...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of neurosurgery. >Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention.
【24h】

Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention.

机译：在磁共振成像上评估轴内增强性脑肿瘤：加多贝酸二聚丁二胺和g多戊酸二聚丁二胺的内在交叉比较，用于可视化和评估，以及对外科手术的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECT: The goal in this article was to compare 0.1 mmol/kg doses of gadobenate dimeglumine (Gd-BOPTA) and gadopentetate dimeglumine, also known as gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA), for enhanced magnetic resonance (MR) imaging of intraaxial brain tumors. METHODS: Eighty-four patients with either intraaxial glioma (47 patients) or metastasis (37 patients) underwent two MR imaging examinations at 1.5 tesla, one with Gd-BOPTA as the contrast agent and the other with Gd-DTPA. The interval between fully randomized contrast medium administrations was 2 to 7 days. The T1-weighted spin echo and T2-weighted fast spin echo images were acquired before administration of contrast agents and T1-weighted spin echo images were obtained after the agents were administered. Acquisition parameters and postinjection acquisition times were identical for the two examinations in each patient. Three experienced readers working in a fully blinded fashion independently evaluated all images for degree and quality of available information (lesion contrast enhancement, lesion border delineation, definition of disease extent, visualization of the lesion's internal structures, global diagnostic preference) and quantitative enhancement (that is, the extent of lesion enhancement after contrast agent administration compared with that seen before its administration [hereafter referred to as percent enhancement], lesion/brain ratio, and contrastoise ratio). Differences were tested with the Wilcoxon signed-rank test. Reader agreement was assessed using kappa statistics. Significantly better diagnostic information/imaging performance (p < 0.0001, all readers) was obtained with Gd-BOPTA for all visualization end points. Global preference for images obtained with Gd-BOPTA was expressed for 42 (50%), 52 (61.9%), and 56 (66.7%) of 84 patients (readers 1, 2, and 3, respectively) compared with images obtained with Gd-DTPA contrast in four (4.8%), six (7.1%), and three (3.6%) of 84 patients. Similar differences were noted forall other visualization end points. Significantly greater quantitative contrast enhancement (p < 0.04) was noted after administration of Gd-BOPTA. Reader agreement was good (kappa > 0.4). CONCLUSIONS: Lesion visualization, delineation, definition, and contrast enhancement are significantly better after administration of 0.1 mmol/kg Gd-BOPTA, potentially allowing better surgical planning and follow up and improved disease management.
机译：目的：本文的目的是比较0.1 mmol / kg剂量的g酸二丁二胺（Gd-BOPTA）和g戊二酸二丁胺（也称为g二亚乙基三胺五乙酸（Gd-DTPA）），以增强轴内磁共振（MR）成像脑肿瘤。方法：84例轴内神经胶质瘤或转移性（37例）患者在1.5 tesla进行了两次MR影像学检查，一名以Gd-BOPTA作为造影剂，另一名以Gd-DTPA治疗。完全随机分配造影剂之间的间隔为2至7天。在给予造影剂之前获取了T1加权的自旋回波图像和T2加权的快速自旋回波图像，而在给予这些试剂后获得了T1加权的自旋回波图像。每个患者的两次检查的采集参数和注射后采集时间相同。三位经验丰富的读者以全盲的方式独立评估了所有图像的可用信息的程度和质量（病变对比增强，病变边界轮廓，疾病范围的定义，病变内部结构的可视化，整体诊断偏好）和定量增强（即即，与施用造影剂之前相比，造影剂施用之后的病变增强程度（以下称为百分数增强），病变/脑比，以及对比度/噪声比）。差异用Wilcoxon符号秩检验进行检验。使用kappa统计数据评估读者的认同感。对于所有可视化终点，使用Gd-BOPTA可获得明显更好的诊断信息/成像性能（p <0.0001，所有读取器）。与使用Gd获得的图像相比，在84位患者（分别为阅读器1、2和3）中，有42位（50％），52位（61.9％）和56位（66.7％）表达了使用Gd-BOPTA获得的图像的总体偏好。 -DTPA在84位患者中有4位（4.8％），6位（7.1％）和3位（3.6％）形成对比。对于所有其他可视化端点，也注意到了类似的差异。给予Gd-BOPTA后，明显提高了定量对比度（p <0.04）。读者的同意很好（kappa> 0.4）。结论：施用0.1 mmol / kg Gd-BOPTA后，病变的可视化，轮廓，清晰度和对比增强效果显着改善，潜在地允许更好的手术计划和随访并改善疾病管理。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号